A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma

No abstract is available for this paper.

• Publication year

  2007

• Venue

  American Journal of Clinical Oncology

• Publication date

  2007-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.coc.0000256104.80089.35PMID 17551310
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis as a prognostic factor in thick cutaneous malignant melanoma

  2014cited by this paper
• Monitoring multiple angiogenesis‐related molecules in the blood of cancer patients shows a correlation between VEGF‐A and MMP‐9 levels before treatment and divergent changes after surgical vs. conservative therapy

  2006cited by this paper
• Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.

  2006cited by this paper
• Metronomic low‐dose chemotherapy as antiangiogenic therapeutic strategy for cancer

  2005cited by this paper
• Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.

  2005cited by this paper
• Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways.

  2005cited by this paper
• A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin

  2005cited by this paper
• Temozolomide plus thalidomide in patients with brain metastases from melanoma

  2005cited by this paper
• Differential Roles of Vascular Endothelial Growth Factor Receptors 1 and 2 in Dendritic Cell Differentiation1

  2005cited by this paper
• A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors

  2005cited by this paper
• Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox‐2 inhibition

  2005cited by this paper
• Dendritic Cells and Vascular Endothelial Growth Factor in Colorectal Cancer: Correlations with Clinicobiological Findings

  2005cited by this paper
• Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.

  2005cited by this paper
• Phase II study of thalidomide in patients with metastatic malignant melanoma

  2004cited by this paper
• Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung

  2004cited by this paper
• Correspondence re: DC Lev et al., Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther, 2003;2(8):753-63.

  2004cited by this paper
• Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

  2004cited by this paper
• Role of dendritic cells in the generation of regulatory T cells.

  2004cited by this paper
• Improvement in efficacy of chemoradiotherapy by addition of an antiangiogenic agent in a murine tumor model.

  2004cited by this paper
• Phase II Study of the Flk-1 Tyrosine Kinase Inhibitor SU5416 in Advanced Melanoma

  2004cited by this paper
• Prognostic value of serum VEGF in melanoma patients: a pilot study.

  2004cited by this paper
• Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate

  2004cited by this paper
• Vasculogenic mimicry has no prognostic significance in pT3 and pT4 cutaneous melanoma.

  2004cited by this paper
• Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.

  2004cited by this paper
• Phase II study of thalidomide in patients with metastatic melanoma

  2004cited by this paper
• Novel therapeutic agents under investigation for malignant melanoma

  2003cited by this paper
• Effect of neoadjuvant chemoradiotherapy on angiogenesis in oesophageal cancer

  2003cited by this paper
• Contrasting effects of VEGF gene disruption in embryonic stem cell‐derived versus oncogene‐induced tumors

  2003cited by this paper
• Inhibition of angiogenesis by non-toxic doses of temozolomide

  2003cited by this paper
• Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.

  2003cited by this paper
• Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.

  2003cited by this paper
• Angiogenesis in cutaneous melanoma: Pathogenesis and clinical implications

  2003cited by this paper
• Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy.

  2003cited by this paper
• Vascular endothelial growth factor‐C expression correlates with lymph node localization of human melanoma metastases

  2003cited by this paper
• Overexpression of vascular endothelial growth factor and its endothelial cell receptor KDR in type 1 leprosy reaction.

  2002cited by this paper
• Inhibition of tumor growth by systemic treatment with thrombospondin‐1 peptide mimetics

  2002cited by this paper
• Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window

  2002cited by this paper
• Immune dysfunction in cancer patients.

  2002cited by this paper
• Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.

  2002cited by this paper
• Regulation of CD36 expression in human melanoma cells.

  2002cited by this paper
• Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1.

  2001cited by this paper
• VEGF as a mediator of tumor-associated immunodeficiency

  2001cited by this paper
• Treatment of metastatic melanoma in the brain with temozolomide and thalidomide.

  2001cited by this paper
• Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor.

  2000cited by this paper
• New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.

  2000cited by this paper
• Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

  2000cited by this paper
• Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

  2000cited by this paper
• A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.

  1999cited by this paper
• Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression.

  1999cited by this paper
• Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.

  1998cited by this paper
• An evaluation of tumour vascularity as a prognostic indicator in uveal melanoma

  1997cited by this paper
• Thrombospondin as a regulator of angiogenesis.

  1997cited by this paper
• Identification of a Domain (155–183) on CD36 Implicated in the Phagocytosis of Apoptotic Neutrophils*

  1996cited by this paper
• Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

  1996cited by this paper
• CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis

  1995cited by this paper
• Inhibition of angiogenesis by thrombospondin-2.

  1995cited by this paper
• Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.

  1995cited by this paper
• Proinflammatory cytokines potentiate thrombospondin-mediated phagocytosis of neutrophils undergoing apoptosis.

  1995cited by this paper
• Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas.

  1994cited by this paper
• Immunohistological Examination Of The Relationship Between Metastatic Potential And Expression Of Adhesion Molecules And ‘Selectins’ On Melanoma Cells

  1994cited by this paper
• Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity

  1993cited by this paper
• Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis.

  1992cited by this paper
• Cellular attachment to thrombospondin. Cooperative interactions between receptor systems.

  1991cited by this paper
• Apoptosis (programmed cell death) and functional changes in aging neutrophils. Modulation by inflammatory mediators.

  1991cited by this paper
• Macrophage vitronectin receptor, CD36, and thrombospondin cooperate in recognition of neutrophils undergoing programmed cell death.

  1991cited by this paper
• The challenge of pulmonary hypertension.

  1991cited by this paper
• A human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum-infected erythrocytes.

  1989cited by this paper
• Isolation of the thrombospondin membrane receptor.

  1987cited by this paper

• Rewiring cancer metabolism: oncogenic signaling pathways and targeted therapeutics

  2025cites this paper
• Lipid metabolism in cancer: Exploring phospholipids as potential biomarkers.

  2025cites this paper
• Thrombospondins: Conserved mediators and modulators of metazoan extracellular matrix

  2024cites this paper
• Metabolic Reprogramming in Tumor Immune Microenvironment: Impact on Immune Cell Function and Therapeutic Implications.

  2024cites this paper
• Unraveling the intricate relationship between lipid metabolism and oncogenic signaling pathways

  2024cites this paper
• Targeting fatty acid uptake and metabolism in cancer cells: A promising strategy for cancer treatment.

  2023cites this paper
• Ligand-dependent CD36 functions in cancer progression, metastasis, immune response, and drug resistance.

  2023cites this paper
• THBS1-producing tumor-infiltrating monocyte-like cells contribute to immunosuppression and metastasis in colorectal cancer

  2023cites this paper
• The Role of CD36 in Cancer Progression and Its Value as a Therapeutic Target

  2023cites this paper
• Resistance to antiangiogenic treatments: A review

  2022cites this paper
• The multifaceted role of Matricellular Proteins in health and cancer, as biomarkers and therapeutic targets.

  2022cites this paper
• Progress of potential drugs targeted in lipid metabolism research

  2022cites this paper
• Reprogramming of Fatty Acid Metabolism in Gynaecological Cancers: Is There a Role for Oestradiol?

  2022cites this paper
• Adding fuel to the fire: The lipid droplet and its associated proteins in cancer progression

  2022cites this paper
• Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity.

  2021cites this paper
• Anti-Angiogenic Therapy: Current Challenges and Future Perspectives

  2021cites this paper
• Functions of Thrombospondin-1 in the Tumor Microenvironment

  2021cites this paper
• Too complex to fail? Targeting fatty acid metabolism for cancer therapy.

  2021cites this paper
• How cancer cells remodel lipid metabolism: strategies targeting transcription factors

  2021cites this paper
• Lipid metabolism in cancer: New perspectives and emerging mechanisms.

  2021cites this paper
• Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma

  2021cites this paper
• Recent advances in the synthesis of C-terminally modified peptides.

  2020cites this paper
• Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

  2020cites this paper
• Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer

  2020influential citation
• Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression

  2020cites this paper
• Effet de l'inhibition par ARN interférence de la thrombospondine-1 sur la potentialisation de la réponse immune dans un contexte tumoral

  2019cites this paper
• Synthetic approaches of naturally and rationally designed peptides and peptidomimetics

  2018cites this paper
• Human expression patterns: qualitative and quantitative analysis of thrombospondin‐1 under physiological and pathological conditions

  2018cites this paper
• CD47, a multi-facetted target for cancer immunotherapy

  2017cites this paper
• The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment

  2017cites this paper
• Predictive model identifies strategies to enhance TSP1-mediated apoptosis signaling

  2017cites this paper
• Proteomic profiling of the cancer cell secretome: informing clinical research

  2017cites this paper
• Transcriptional and Post-Transcriptional Regulation of Thrombospondin-1 Expression: A Computational Model

  2017cites this paper
• Thrombospondin-1 is a multifaceted player in tumor progression

  2017cites this paper
• Thrombospondin-1 is a multifaceted player in tumor progression.

  2017cites this paper
• Thrombospondins: A Role in Cardiovascular Disease

  2017cites this paper
• What mediates the effects of thrombospondin-1 in pulmonary hypertension? New evidence for a dual-pronged role of CD47.

  2017cites this paper
• Targeting tumour angiogenesis in colorectal cancer liver metastases

  2016cites this paper
• The pituitary TGF b 1 system as a novel target for the treatment of resistant prolactinomas

  2016cites this paper
• Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

  2016cites this paper
• Original insights on thrombospondin-1-related antireceptor strategies in cancer

  2015cites this paper
• Chapter 11 - Other Nonbiological Approaches to Targeted Cancer Chemotherapy

  2015cites this paper
• Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration

  2015cites this paper
• Peptide inhibitors of angiogenesis in endometriosis and the female reproductive system

  2014cites this paper
• Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma

  2014cites this paper
• Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma – implications for therapeutic strategies and targeted therapies

  2014cites this paper
• A novel cancer therapeutic using thrombospondin 1 in dendritic cells.

  2014cites this paper
• Thrombospondin-1 in Urological Cancer: Pathological Role, Clinical Significance, and Therapeutic Prospects

  2013cites this paper
• Molecular Basis of Antiangiogenic Thrombospondin-1 Type 1 Repeat Domain Interactions With CD36

  2013cites this paper
• Animal models for anti-angiogenic therapy in endometriosis.

  2013cites this paper
• Stem Cell‐Based Antiangiogenic Therapies for Brain Tumors

  2013cites this paper
• Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1.

  2013cites this paper
• Inhibition of Angiogenesis for the Treatment of Metastatic Melanoma

  2013cites this paper
• antithrombotic activity of nitric oxide/cGMP signaling Thrombospondin-1 stimulates platelet aggregation by blocking the

  2013cites this paper
• Noncanonical roles of the immune system in eliciting oncogene addiction.

  2013cites this paper
• Mécanismes de progression des carcinomes de la prostate et recherche de nouveaux facteurs pronostiques

  2013cites this paper
• Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.

  2012cites this paper
• Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1).

  2012cites this paper
• Antiangiogenic and anticancer molecules in cartilage

  2012cites this paper
• Role of the Thrombospondin - CD36 - Histidine Rich Glycoprotein Pathway in Tumor Growth and Angiogenesis

  2012cites this paper
• Is Age ≥ 70 Years an Important Predictor of Adverse Events Among Patients Enrolled in Metastatic Melanoma Trials? Findings from Pooled Analyses of Therapeutic Trials.

  2012cites this paper
• The use of Thrombospondin-1 Mimetic Peptides for the Treatment of Epithelial Ovarian Cancer

  2012cites this paper
• Context Dependent Role of the CD36 - Thrombospondin - Histidine-Rich Glycoprotein Axis in Tumor Angiogenesis and Growth

  2012cites this paper
• Caracterización del sistema TGF-ß1 hipofisario: en búsqueda de un blanco terapéutico para prolactinomas resistentes a agonistas dopaminérgicos

  2012cites this paper
• Rôle de la thrombospondine-1 dans la migration, l’invasion et la dissémination métastatique dans les carcinomes prostatiques et mammaires

  2012cites this paper
• The thrombospondins.

  2011cites this paper
• Advanced Prostate Tumors Thrombospondin-1 Triggers Cell Migration and Development of Updated

  2011cites this paper
• Anti-angiogenic peptides for cancer therapeutics.

  2011cites this paper
• Therapies using anti-angiogenic peptide mimetics of thrombospondin-1

  2011cites this paper
• Thrombospondin-1 triggers cell migration and development of advanced prostate tumors.

  2011cites this paper
• ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer

  2011cites this paper
• Preclinical Development ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer

  2011cites this paper
• Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors

  2010cites this paper
• Id1 overexpression is independent of repression and epigenetic silencing of tumor suppressor genes in melanoma

  2010cites this paper
• The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.

  2010cites this paper
• Oxidative stress in tumor angiogenesis- therapeutic targets.

  2010cites this paper
• A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early-antral follicles in vivo.

  2010cites this paper
• Anticancer Role of PPARγ Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes

  2010cites this paper
• PPARs and Anticancer Therapies

  2010cites this paper
• Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action

  2010cites this paper
• Results of a multicenter, randomized, double‐blind, dose‐evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma

  2009cites this paper
• ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer

  2009cites this paper
• Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.

  2009cites this paper
• Results of a multicenter, randomized, double‐blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma

  2009cites this paper
• ABT-510 Is an Effective Chemopreventive Agent in the Mouse 4-Nitroquinoline 1-Oxide Model of Oral Carcinogenesis

  2009cites this paper
• Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies

  2009cites this paper
• Angiogenesis in cutaneous disease: part II.

  2009cites this paper
• Novel therapeutics for the treatment of metastatic melanoma.

  2009cites this paper
• Angiogenesis in cutaneous disease: part I.

  2009cites this paper
• Thrombospondin‐1 modulates vascular endothelial growth factor activity at the receptor level

  2009cites this paper
• Novel approaches in anti-angiogenic treatment targeting endothelial F-actin: a new anti-angiogenic strategy?

  2008cites this paper
• Extracellular matrix retention of thrombospondin 1 is controlled by its conserved C-terminal region

  2008cites this paper
• Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.

  2008cites this paper
• Clinical approaches toward tumor angiogenesis: past, present and future.

  2008cites this paper
• Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling.

  2008cites this paper
• Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells.

  2008cites this paper
• Role of Melanoma Secreted Thrombospondin-1 on Induction of Immunosuppressive Regulatory T Cells through CD47

  2008cites this paper
• New molecular targets in angiogenic vessels of glioblastoma tumours

  2008cites this paper
• Thrombospondins: from structure to therapeutics

  2008cites this paper
• A journey in structure-based drug discovery: from designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents.

  2007cites this paper